Clinical Trials Logo

Clinical Trial Summary

This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03669640
Study type Interventional
Source Hoffmann-La Roche
Contact
Status Terminated
Phase Phase 2
Start date December 4, 2018
Completion date May 8, 2023

See also
  Status Clinical Trial Phase
Completed NCT04512066 - A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder Phase 2
Completed NCT02192593 - Computerized Cognitive-Behavioral Therapy for Auditory Hallucinations N/A
Completed NCT00224315 - Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial Phase 4
Recruiting NCT02808533 - Topiramate and Schizophrenia: Effects on Weight and Psychopathology N/A
Not yet recruiting NCT06319170 - Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder. Phase 1